Ghent, October 24th, 2023.
We are happy to announce that BioLizard has joined the Da’s Geniaal consortium.
The Da’s Geniaal consortium aims to inspire youngsters between 10 and 14 years to take on more science and technology oriented studies, with a focus on girls in that age group.
By joining Da’s Geniaal, BioLizard joins an ambitious and diverse group of large and small companies and for-profit and non-profit organisations, spread across different industries and regions. Currently, the main focus of Da’s Geniaal is within Belgium.
The ambitions of Da’s Geniaal are an ideal match for BioLizard’s goals around sustainability, diversity, equity, and inclusion.
We look forward to working with Da’s Geniaal to help young people aged 10 to 14 to discover the scientist within themselves – and to discover how cool science and technology can be!
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
